Skip to main
CV
CV logo

CapsoVision Inc (CV) Stock Forecast & Price Target

CapsoVision Inc (CV) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CapsoVision Inc. has achieved significant milestones with its CapsoCam Plus device, being utilized in over 135,000 procedures and generating nearly $12 million in revenue for 2024. The consistent annual revenue growth since the company's launch in the U.S. demonstrates a robust demand for its innovative endoscopic video imaging technology. With a solid market presence in gastrointestinal imaging and ongoing development of the CapsoColon 3D for the large intestines, CapsoVision holds a favorable outlook for future expansion and profitability.

Bears say

CapsoVision Inc faces significant challenges that may impede its revenue growth, primarily due to resistance from healthcare providers and patients concerning the retrieval of its endoscopic capsules, which could delay the path to profitability. Furthermore, potential disruptions in manufacturing, adverse clinical outcomes, or product recalls may lead to diminished investor confidence and negatively affect revenue streams. Lastly, the need for CE mark approval may constrain the market availability of CapsoCam Plus, especially as the company seeks to expand into pediatric applications and fully digestible technologies.

CapsoVision Inc (CV) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CapsoVision Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CapsoVision Inc (CV) Forecast

Analysts have given CapsoVision Inc (CV) a Buy based on their latest research and market trends.

According to 1 analysts, CapsoVision Inc (CV) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CapsoVision Inc (CV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.